DOD Strategically and Remarkably Takes a Huge Step Forward
From a supplementary OEM producer to acquire a business in producing OEM for skincare products, then gets selected as a distributor in Chinese TV Shopping, DOD has got it all.
DOD Biotech Public Company Limited (DOD) has been in the radar of investors since its first trading day in mai on June 20, 2018. Both analysts and investors projected that the share was fundamentally strong with its business as a leading supplementary OEM producer for top supplementary brands. DOD also created its own supplementary under the brand “Dai a to” even though it aggregates to only a small portion of DOD’s business that focuses in OEM.
On its 3Q18 financial statement, DOD booked ฿296 million of profit from a total of ฿606 million revenue. Its net profit ratio was at 48.83%.
An optimistic view and even higher expectation from investors came around the end of 2018 after the company had taken over PCCA Laboratory Co., Ltd. (PCCA) to start producing OEM cosmetic and skincare products.
The deal that DOD made might seem like normal business expansion, but strategically speaking, this is for a completion of its business range. DOD originally owned only supplementary business which is things that needed to be consumed (eat/drink), but the acquisition of PCCA business would add products that needed to be applied on a body to DOD. This is a whole new range of business that can diversify risks for DOD if somehow its original business tanked.
DOD did not just fulfill its business range, but also took another solid step forward.
Another remarkable point that makes DOD very interesting is the advertisement in Chinese media. DOD was the sole company to be selected to commercialize in TV shopping as the distributor of supplements, Thai herb vitamin, nostrum, and skin care for more than 20 channels of China Central Television (CCTV). This had boosted the opportunity of conquering the Chinese market even more.
It was not a surprise on a recent plunge of DOD’s share as the company just issued an interim dividend with an ex-dividend on January 2, 2019.
The share is still solid and very promising when looking at its fundamental, so do not panic over a short-term plummet.